CN105073108A - L-4-氯犬尿氨酸的剂型和治疗用途 - Google Patents

L-4-氯犬尿氨酸的剂型和治疗用途 Download PDF

Info

Publication number
CN105073108A
CN105073108A CN201480010060.XA CN201480010060A CN105073108A CN 105073108 A CN105073108 A CN 105073108A CN 201480010060 A CN201480010060 A CN 201480010060A CN 105073108 A CN105073108 A CN 105073108A
Authority
CN
China
Prior art keywords
chlorine
kynurenin
pharmaceutical composition
administration
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480010060.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·拉尔夫·斯诺德格拉斯
艾伦·E·加图
杰克·S·希克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Priority to CN202110387961.2A priority Critical patent/CN112933073A/zh
Priority to CN202110384159.8A priority patent/CN113116877A/zh
Priority to CN202110387953.8A priority patent/CN113209068A/zh
Publication of CN105073108A publication Critical patent/CN105073108A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
  • Quinoline Compounds (AREA)
CN201480010060.XA 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途 Pending CN105073108A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202110387961.2A CN112933073A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110384159.8A CN113116877A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110387953.8A CN113209068A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361849191P 2013-01-22 2013-01-22
US61/849,191 2013-01-22
PCT/US2014/012598 WO2014116739A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses l-4-chlorokynurenine

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110387953.8A Division CN113209068A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110387961.2A Division CN112933073A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110384159.8A Division CN113116877A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途

Publications (1)

Publication Number Publication Date
CN105073108A true CN105073108A (zh) 2015-11-18

Family

ID=51228003

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110387961.2A Pending CN112933073A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110387953.8A Pending CN113209068A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN201480010060.XA Pending CN105073108A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110384159.8A Pending CN113116877A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202110387961.2A Pending CN112933073A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途
CN202110387953.8A Pending CN113209068A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110384159.8A Pending CN113116877A (zh) 2013-01-22 2014-01-22 L-4-氯犬尿氨酸的剂型和治疗用途

Country Status (22)

Country Link
US (8) US9993450B2 (https=)
EP (4) EP2948140B1 (https=)
JP (5) JP6436913B2 (https=)
KR (5) KR20230003410A (https=)
CN (4) CN112933073A (https=)
AU (5) AU2014209466B2 (https=)
BR (1) BR112015017535A2 (https=)
CA (3) CA3128321C (https=)
CY (1) CY1122403T1 (https=)
DK (3) DK3228313T3 (https=)
ES (3) ES2980120T3 (https=)
HK (1) HK1217170A1 (https=)
HR (2) HRP20240812T1 (https=)
HU (1) HUE067381T2 (https=)
IL (3) IL291831B1 (https=)
MX (2) MX375318B (https=)
PL (2) PL3598971T3 (https=)
PT (3) PT3598971T (https=)
RS (1) RS59687B1 (https=)
SI (2) SI3228313T1 (https=)
WO (1) WO2014116739A1 (https=)
ZA (2) ZA201505569B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020088270A1 (zh) * 2018-10-29 2020-05-07 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
WO2017044516A1 (en) * 2015-09-08 2017-03-16 Cephalon, Inc. Prodrugs of chlorokynurenines
CN118026866A (zh) 2018-02-09 2024-05-14 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306674A1 (en) * 2010-06-15 2011-12-15 Gruenenthal Gmbh Pharmaceutical Combination

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5360814A (en) 1991-02-28 1994-11-01 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
WO2003015713A2 (en) 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
EP1903028A1 (en) * 2006-09-22 2008-03-26 Werner Tschollar Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20110190347A1 (en) 2008-08-21 2011-08-04 Richter Gedeon Nyrt. Methods for treating neuropathic pain
ES2612948T3 (es) 2009-04-23 2017-05-19 Universität Zürich Bloqueantes del receptor de NMDA para el tratamiento de anemia falciforme
BRPI1014247A2 (pt) * 2009-06-17 2016-04-12 Targacept Inc reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.
DK2466312T3 (da) 2009-08-12 2020-01-13 Human Metabolome Tech Inc Phosphoethanolamine som biomarkør for depression
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
WO2014152835A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
US9745342B2 (en) 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
JP2018521007A (ja) 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306674A1 (en) * 2010-06-15 2011-12-15 Gruenenthal Gmbh Pharmaceutical Combination

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER PITTENGER ET AL.: "The NMDA receptor as a therapeutic target in major depressive disorder", 《CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS》 *
HUI-QIU WU ET AL.: "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", 《 EUROPEAN JOURNAL OF PHARMACOLOGY》 *
PETRA DUNKEL ET AL.: "Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis", 《 EXPERT OPIN. INVESTIG. DRUGS》 *
不详: "VistaGen Therapeutics Inc. (VSTA) on Path to Higher Exchange", 《HTTP://SEEKINGALPHA.COM/INSTABLOG/783255-MISSIONIR/213928-VISTAGEN-THERAPEUTICS-INC-VSTA-ON-PATH-TO-HIGHER-EXCHANGE》 *
周宁娜等: "抑郁症治疗的新靶点:COX-2", 《精神医学杂志》 *
楼剑书等: "免疫激活对抑郁症谷氨酸和五羟色胺系统的调节", 《中国药理学通报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020088270A1 (zh) * 2018-10-29 2020-05-07 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用

Also Published As

Publication number Publication date
EP4385563A3 (en) 2024-08-21
KR20210149905A (ko) 2021-12-09
SI3228313T1 (sl) 2019-12-31
AU2018253600B2 (en) 2020-07-09
EP2948140A1 (en) 2015-12-02
US9993450B2 (en) 2018-06-12
AU2024278564A1 (en) 2025-01-09
ZA201607581B (en) 2019-04-24
EP3598971B1 (en) 2024-03-20
ES2751138T3 (es) 2020-03-30
US20250161251A1 (en) 2025-05-22
EP2948140A4 (en) 2016-08-03
AU2018253600A1 (en) 2018-11-22
MX375318B (es) 2025-03-06
HRP20240812T1 (hr) 2024-09-27
CY1122403T1 (el) 2021-01-27
HRP20192189T1 (hr) 2020-02-21
SI3598971T1 (sl) 2024-10-30
JP6804497B2 (ja) 2020-12-23
EP4385563A2 (en) 2024-06-19
PL3598971T3 (pl) 2024-09-09
US20190133984A1 (en) 2019-05-09
JP6436913B2 (ja) 2018-12-12
JP7021298B2 (ja) 2022-02-16
US20180289649A1 (en) 2018-10-11
PT3598971T (pt) 2024-06-20
AU2014209466B2 (en) 2018-11-08
PL3228313T3 (pl) 2020-03-31
NZ710121A (en) 2021-01-29
EP3228313A1 (en) 2017-10-11
US9993453B2 (en) 2018-06-12
AU2014209466A1 (en) 2015-08-06
IL276126A (en) 2020-08-31
CN113116877A (zh) 2021-07-16
CA2898619C (en) 2021-10-19
US20220409564A1 (en) 2022-12-29
KR102335919B1 (ko) 2021-12-07
KR20230098711A (ko) 2023-07-04
US10617663B2 (en) 2020-04-14
EP3598971A1 (en) 2020-01-29
US20180369180A1 (en) 2018-12-27
US10632091B2 (en) 2020-04-28
AU2022221382A1 (en) 2022-09-15
KR20210063449A (ko) 2021-06-01
HK1217170A1 (zh) 2016-12-30
CA3128321C (en) 2023-12-05
US20160158178A1 (en) 2016-06-09
MX2015009277A (es) 2015-12-11
DK3228313T3 (da) 2019-11-25
IL291831B1 (en) 2026-04-01
JP2020183400A (ja) 2020-11-12
JP2019023195A (ja) 2019-02-14
US20190125707A1 (en) 2019-05-02
US10980758B2 (en) 2021-04-20
HUE067381T2 (hu) 2024-10-28
JP2016505050A (ja) 2016-02-18
AU2020204420A1 (en) 2020-07-23
DK3598971T3 (da) 2024-06-10
CN113209068A (zh) 2021-08-06
WO2014116739A1 (en) 2014-07-31
BR112015017535A2 (pt) 2020-02-04
IL291831A (en) 2022-06-01
US20150359772A1 (en) 2015-12-17
RS59687B1 (sr) 2020-01-31
JP2022070894A (ja) 2022-05-13
CA3128321A1 (en) 2014-07-31
KR20150109428A (ko) 2015-10-01
CN112933073A (zh) 2021-06-11
ES2635353T3 (es) 2017-10-03
US12036198B2 (en) 2024-07-16
IL240090B (en) 2020-08-31
ZA201505569B (en) 2017-01-25
CA2898619A1 (en) 2014-07-31
EP2948140B1 (en) 2017-05-10
DK2948140T3 (en) 2017-08-21
PT2948140T (pt) 2017-08-10
AU2022221382B2 (en) 2024-09-19
EP3228313B1 (en) 2019-09-11
ES2980120T3 (es) 2024-09-30
KR102257284B1 (ko) 2021-05-28
PT3228313T (pt) 2019-12-17
CA3216579A1 (en) 2014-07-31
JP2024069257A (ja) 2024-05-21
KR20230003410A (ko) 2023-01-05
MX2020009966A (es) 2020-10-12
IL276126B (en) 2022-05-01
IL240090A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
CN105073108A (zh) L-4-氯犬尿氨酸的剂型和治疗用途
CN117503775A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
AU2023202003A1 (en) Melatonin mini-tablets and method of manufacturing the same
CN113456648A (zh) 丹参酮ⅱa磺酸钠的新用途及其制剂
Sankar et al. Oral disintegration tablets of stavudine for HIV management: a new technological approach
HK40059702A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40056816A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
Díaz Vélez Pharmacokinetics of oral tetrahydrocannabinol and cannabidiol in humans: a systematic critical review
HK40054519A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
Akin-Ajani et al. Comparative quality assessment of selected fluconazole brands in Ibadan, Nigeria: Évaluation comparative de la qualité de certaines marques de fluconazole à Ibadan, au Nigéria
CN117320702A (zh) 用大麻二酚和包含大麻二酚的药物组合物优化精神障碍治疗的方法
Seabi Formulation of carbamazepine and sodium valproate fixed dose combination for management of epilepsy
Shukla et al. Design and in-vitro evaluation of oro-dispersible tablets of oseltamivir phosphate
Kodam et al. Formulation and evaluation of Tramadol Hydrochloride sustained matrix tablets
Revathi et al. Formulation and In-vitro Evaluation of Oro Dispersible Tablet using phenylephrine Hydrochloride as model drug
HK40025020A (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN109953995A (zh) 一种药物组合物及其在制备催眠类药物中的用途
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
Strojil et al. Oc029—Interaction Between Mycophenolate Mophetil And Tacrolimus In Kidney Graft Recipients
CN102579383A (zh) 右佐匹克隆缓释片

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217170

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20151118

RJ01 Rejection of invention patent application after publication